Abstract
The antitumor effects of two polyamine antimetabolites, alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG), when combined with cis-diamminedichlroplatinum (CDDP) or mitomycin C (MMC), were studied using human gastric cancer cells xenotransplanted into nude mice. DFMO 1000 mg/kg and MGBG 50 mg/kg were given intraperitoneally for 6 successive days, while CDDP 3 mg/kg or MMC 2 mg/kg was given every second day. Although DFMO and MGBG plus MMC did suppress the tumor growth, the combination with CDDP led to no suppression, and rapid growth occurred after the cessation of therapy. The inhibition of tumoral DNA biosynthesis and a decline in polyamine levels, were also not observed. The polyamine antimetabolites when used with CDDP did not produce the desired antitumor efficacy, even though the platinum concentration in the tumor tissue was high. On the contrary, however, DFMO and MGBG when combined with MMC did suppress tumor growth, inhibited DNA biosynthesis, and tissue polyamine levels were low. These results suggest that though CDDP and MMC belong to a similar category of DNA attacking, bifunctional alkylating agents, the findings of these two drugs are contradictory. Here, the mechanism of action no doubt plays a contributory role.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Verma DS, Sunkara PS. An essential role for polyamine biosynthesis during human granulopoietic differentiation. Cancer Res 1982; 42: 3046–3049.
Janne J, Poso H, Raina A. Polyamines in rapid growth and cancer. Biochem Biophys Acta 1978; 473: 241–293.
Abeloff MD, Slavik M, Luk GD, Griffin CA, Herman J, Blanc O, Sjoerdsma A, Baylin SB. Phase I trial and pharmacokinetic studies of α-difluoromethyl-ornithine—an inhibitor of polyamine biosynthesis. J Clin Oncol 1984; 2: 124–130.
Mihich E, Simpson CL, Mulhern AI. Pharmacology of methylglyoxal-bis-(guanylhydrazone) (CH3-G). Cancer Res 1962; 22: 962–973.
Herr HW, Kleinert EL, Conti PS, Burchenal H, Whitmore WF Jr. Effects of α-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice. Cancer Res 1984; 44: 4382–4385.
Liquori AM, Constantino L, Crescenzi V, Elia V, Giglo E, Puliti R, De Santis Savino M, Vitagliano V. Complexes between DNA and polyamines: a molecular model. J Mol Biol 1967; 24: 113–122.
Hung DT, Marton LJ, Deen DF, Shafer RH. Depletion of intracellular polyamines may alter DNA conformation in 9L rat brain tumor cells. Science 1983; 221: 368–370.
Ovejera AA, Houchens DP, Barker AD. Chemotherapy of human xenografts in genetically athymic mice. Ann Clin Lab Sci 1978; 8: 50–56.
Brown WO, Badman HG. Liquid-scintillation counting of14C-labelled animal tissues at high efficiency. Biochem J 1961; 78: 571–578.
Yoshida H, Nakajima T. Prompt microassay of amino acids and amines by the use of high performance liquid chromatography. In: Tamura Z ed, Advances in clinical chemistry. Tokyo: Gakkai Shuppan Center 1980; 323–338.
LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977; 18: 184–191.
Warrell RP, Burchanel JH. Methylglyoxal-bis(guanylhydrazone) (methyl-GAG): Current status and future prospects. J Clin Oncol 1983; 1: 52–65.
Sunkara PS, Chang CC, Prakash NJ, Lachmann PJ. Effect of inhibition of polyamine biosynthesis by DL-α-difluoromethylornithine on the growth and melanogenesis of B 16 melanomain vitro andin vivo. Cancer Res 1985; 45: 4067–4070.
Fujimoto S, Igarashi K, Shrestha RD, Miyazaki M, Okui K Antitumor effects of two polyamine antimetabolites combined with mitomycin C on human stomach cancer cells xenotransplanted into nude mice. Int J Cancer 1985; 35: 821–825.
Fujimoto S, Igarashi K, Shrestha RD, Miyazaki M, Endoh F, Ohta M, Togawa Y, Okui K. Combined therapy of polyamine antimetabolites and antitumor drugs for human gastric cancer xenotransplanted into nude mice. Jpn J Surg 1986; 16: 133–139.
Iyer VN, Szybalski W. A molecular mechanism of mitomycin C action: Linking of complementary DNA strands. Microbiol 1963; 50: 355–362.
Roberts JJ, Thomson AJ. The mechanism of action of antitumor platinum compounds. Prog Nucl Acid Res Mol Biol 1979; 22: 71–133.
Oredsson SM, Deen DF, Marton LJ. Decreased cytotoxicity of cis-diamminedichloroplatinum (II) by α-difluoromethylornithine depletion of polyamines in 9L rat brain tumor cellsin vitro. Cancer Res 1982; 42: 1296–1299.
Kelman AD, Peresie HJ. Mode of DNA binding of cis-platinum (II) antitumor drugs: A base sequence dependent mechanism is proposed. Cancer Treat Rep 1969; 63: 1445–1452.
Stryer L. Biochemistry. San Franscisco: WH Freeman and Co, 1981; 559–596.
Lipsett MN, Weissbach A. The site of alkylation of nucleic acids by mitomycin. Biochemistry 1965; 4: 206–211.
Tomasz M, Mercado CM, Olson J, Chatterjie N. The mode of mitomycin C with deoxyribonucleic acid and other polynucleotidesin vitro. Biochemistry 1974; 13: 4878–4887.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shrestha, R.D., Fujimoto, S. & Okui, K. Contradictory antitumor efficacies produced by the combination of DNA attacking drugs and polyamine antimetabolites. The Japanese Journal of Surgery 17, 263–268 (1987). https://doi.org/10.1007/BF02470698
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02470698